Interstitial lung disease is common in RA, occurring in approximately 8% of RA patients. It is associated with a poor prognosis, and a median survival of 3 years. This important condition has often been neglected within the spectrum of RA research. That is changing, with excellent research initiatives presented at ACR22. I am going to highlight two select abstracts from Monday’s dedicated RA-ILD session.

Conferences are held for the purposes of sharing ideas, developing new relationships, and collaborating on future research. The American College of Rheumatology (ACR) Convergence 2022 meeting embodies all these ideals by offering both in-person and virtual attendance options. However, when a conference ends, what happens to the attendees? Will they remember what they learned? Will they incorporate new ideas into their practice?